2024
Editorial for the themed issue: Addressing the dual challenges of opioid use disorder and chronic pain in the context of the opioid crisis
Sofuoglu M, MacLean R, De Aquino J. Editorial for the themed issue: Addressing the dual challenges of opioid use disorder and chronic pain in the context of the opioid crisis. British Journal Of Clinical Pharmacology 2024, 90: 2960-2961. PMID: 39340184, PMCID: PMC11604519, DOI: 10.1111/bcp.16273.Peer-Reviewed Original ResearchSex differences in comorbid pain and opioid use disorder: A scoping review
DeVito E, Ameral V, Sofuoglu M. Sex differences in comorbid pain and opioid use disorder: A scoping review. British Journal Of Clinical Pharmacology 2024, 90: 3067-3083. PMID: 39168150, PMCID: PMC11604518, DOI: 10.1111/bcp.16218.Peer-Reviewed Original ResearchOpioid use disorderChronic painTreatment of opioid use disorderChronic opioid usePost hoc analysisPersistent painClinical courseOpioid useComorbid painSex/gender differencesOpioid misuseOpioidPainUse disorderHighest prevalencePost-hocOutcome variablesDisordersTreatmentHuman subjectsBiological underpinningsPsychosocial factorsTreatment effectsSex differencesSexThe combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial
Yoon G, Sofuoglu M, Petrakis I, Pittman B, Bell M. The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial. Contemporary Clinical Trials 2024, 145: 107657. PMID: 39111388, PMCID: PMC11423257, DOI: 10.1016/j.cct.2024.107657.Peer-Reviewed Original ResearchCognitive remediation therapyAlcohol use disorderAlcohol use disorder treatment outcomesNeurocognitive functionCombination of donepezilRemediation therapyUse disorderTreatment outcomesDevelopment of alcohol use disordersReduce heavy drinking daysHeavy drinking daysGlobal neurocognitive functioningImprove neurocognitive functionEnhanced neurocognitive functionImprove cognitive functionRandomized controlled trialsReduce alcohol consumptionNeurobiological evidenceDrinking daysNeurocognitive function scoresCognitive trainingVA Connecticut Healthcare SystemCognitive functionImprove treatment outcomesCognitive impairmentPulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans
Parida S, MacLean R, Gueorguieva R, Sofuoglu M. Pulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans. Psychopharmacology 2024, 241: 1915-1922. PMID: 38970644, DOI: 10.1007/s00213-024-06609-6.Peer-Reviewed Original ResearchDiscriminative stimulus effectsAddiction thresholdNicotine doseDiscriminative stimulus effects of nicotineStimulus effects of nicotineNicotine deliveryEffects of nicotineOvernight abstinenceStimulus effectsNicotine infusionSubjective effectsTest sessionsNicotineMethodsEleven participantsInfusion procedureLow dosesParticipantsThreshold doseConclusionsTheseAbstinenceDoseHeart rateInfusionSmokingObjectivesToA Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSD
Palmisano A, Meshberg-Cohen S, Petrakis I, Sofuoglu M. A Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSD. Psychological Trauma Theory Research Practice And Policy 2024, 16: 768-783. PMID: 36595460, DOI: 10.1037/tra0001410.Peer-Reviewed Original ResearchPosttraumatic stress disorderBehavioral treatment outcomesEvidence-based treatmentsCognitive controlThreat processingBody of researchPTSD outcomesPTSD treatmentPaucity of researchStress disorderPreliminary supportIntermediate phenotypesTreatment dropoutMethodological limitationsStudy limitationsTreatment effectsCurrent researchTreatment approachesStrong conclusionsNovel treatment approachesEmpirical studyTreatment outcomesTreatment efficacyResearchMemoryEXAMINING RACIAL DIFFERENCES IN SMOKING-RELATED OUTCOMES IN HUMANS DURING EARLY ABSTINENCE AND AFTER INTRAVENOUS NICOTINE INFUSION
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. EXAMINING RACIAL DIFFERENCES IN SMOKING-RELATED OUTCOMES IN HUMANS DURING EARLY ABSTINENCE AND AFTER INTRAVENOUS NICOTINE INFUSION. Drug And Alcohol Dependence 2024, 260: 110027. DOI: 10.1016/j.drugalcdep.2023.110027.Peer-Reviewed Original ResearchW82 Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder
Wolkowicz N, Sofuoglu M, De Aquino J, MacLean R. W82 Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder. Drug And Alcohol Dependence 2024, 260: 110700. DOI: 10.1016/j.drugalcdep.2023.110700.Peer-Reviewed Original ResearchS31 Sex-Specific Associations Between Childhood Trauma and Tobacco Use Outcomes
Palmisano A, Schwartz E, Sofuoglu M. S31 Sex-Specific Associations Between Childhood Trauma and Tobacco Use Outcomes. Drug And Alcohol Dependence 2024, 260: 110142. DOI: 10.1016/j.drugalcdep.2023.110142.Peer-Reviewed Original ResearchW68 Greater Coupling of Pain Intensity and Opioid Craving After Delaying Methadone Dose Among Veterans With Opioid Use Disorder
MacLean R, Spinola S, Pittman B, Meyerovich J, Szollosy S, Wolkowicz N, Sofuoglu M. W68 Greater Coupling of Pain Intensity and Opioid Craving After Delaying Methadone Dose Among Veterans With Opioid Use Disorder. Drug And Alcohol Dependence 2024, 260: 110686. DOI: 10.1016/j.drugalcdep.2023.110686.Peer-Reviewed Original ResearchA preliminary investigation of the acute effects of delta-9-tetrahydrocannabinol on pain and opioid attentional bias among persons with opioid use disorder
Wolkowicz N, Sofuoglu M, Pittman B, Meyerovich J, MacLean R, De Aquino J. A preliminary investigation of the acute effects of delta-9-tetrahydrocannabinol on pain and opioid attentional bias among persons with opioid use disorder. Journal Of Psychiatric Research 2024, 177: 90-95. PMID: 38991269, PMCID: PMC11371499, DOI: 10.1016/j.jpsychires.2024.06.047.Peer-Reviewed Original ResearchAttentional biasOpioid use disorderDelta-9-tetrahydrocannabinolTHC administrationDose of methadoneOpioid cuesUse disorderEffects of delta-9-tetrahydrocannabinolLower doses of methadoneVisual probe taskHigher doses of methadoneEffects of cannabinoidsFive-hour sessionTHC doseOral THCProbe taskPsychoactive constituentAddictive propertiesMethadone patientsMethadone doseWithin-subjectTHCPreliminary evidenceMethadoneAcute effectsHealth correlates of experiential and behavioral avoidance among trauma-exposed veterans
Schwartz E, Palmisano A, Petrakis I, Pietrzak R, Sofuoglu M. Health correlates of experiential and behavioral avoidance among trauma-exposed veterans. Journal Of Psychiatric Research 2024, 176: 213-217. PMID: 38878649, DOI: 10.1016/j.jpsychires.2024.06.014.Peer-Reviewed Original ResearchTrauma-exposed veteransExperiential avoidanceBehavioral avoidanceAnxiety symptomsDepressive symptomsMental health outcomesCognitive dysfunctionPhysical healthPhysical health outcomesHealth outcomesQuality of lifeHealth-related dysfunctionTrauma historyPsychosocial functioningCognitive functionAvoidance behaviorOutcome measuresHealth-related quality of lifeTreatment targetDistressExploratory analysisVeteransHealth-related qualityAvoidanceAnxietyGlial modulators as novel therapeutics for comorbid pain and opioid use disorder
Schwartz E, De Aquino J, Sofuoglu M. Glial modulators as novel therapeutics for comorbid pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024, 90: 3054-3066. PMID: 38752593, DOI: 10.1111/bcp.16094.Peer-Reviewed Original ResearchOpioid use disorderChronic painGlial modulationNovel treatment approachesComorbid painPublic health problemTreatment approachesImproved pain measuresLiterature search of PubMedIncreased opioid prescriptionsSearch of PubMedAddiction-related outcomesSignificant public health problemComorbid disordersOpioid prescriptionsGoogle Scholar databasesPain measuresHealth problemsPain managementClinical studiesTreatment challengesClinical trialsPatient populationPainGlial activationFrom taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder
Weleff J, Nunes J, Costa G, Sofuoglu M, MacLean R, De Aquino J. From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024, 90: 3036-3053. PMID: 38627909, PMCID: PMC11480258, DOI: 10.1111/bcp.16045.Peer-Reviewed Original ResearchOpioid use disorderChronic painLong-term opioid therapyManagement of chronic painPain management alternativeOpioid-induced analgesiaInnovative treatment optionsManagement of painReverse painCentral sensitizationOpioid therapyPain controlTreatment optionsClinical challengeClinical trialsPainPotential therapeutic applicationsPain experiencePotential of psychedelicsNovel therapeuticsHuman evidenceOpioid crisisNeurobiological substratesOpioidExploration of novel therapeuticsEfficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment
MacLean R, Ankawi B, Driscoll M, Gordon M, Frankforter T, Nich C, Szollosy S, Loya J, Brito L, Ribeiro M, Edmond S, Becker W, Martino S, Sofuoglu M, Heapy A. Efficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment. JMIR Research Protocols 2024, 13: e54342. PMID: 38506917, PMCID: PMC10993119, DOI: 10.2196/54342.Peer-Reviewed Original ResearchThe relationship of pain intensity and opioid craving with delayed methadone dose: A preliminary study of individuals with opioid use disorder
MacLean R, Spinola S, Pittman B, Meyerovich J, Szollosy S, Wolkowicz N, Minnix S, Sofuoglu M. The relationship of pain intensity and opioid craving with delayed methadone dose: A preliminary study of individuals with opioid use disorder. British Journal Of Clinical Pharmacology 2024, 90: 2977-2984. PMID: 38439592, DOI: 10.1111/bcp.16027.Peer-Reviewed Original ResearchCold pressor testMethadone doseExperience of painOpioid cravingMethadone conditionTime course of painRelationship of pain intensityDose conditionsCourse of painAssessment of painOpioid use disorderCross-over designPain intensityPain thresholdIncreased riskPainStudy visitsPressor testDelayed dosesUse disorderCravingOpioidMethadone treatmentDoseMethadone
2023
Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder
Rogan M, Nunes J, Xie C, Sofuoglu M, Pittman B, De Aquino J. Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder. American Journal On Addictions 2023, 33: 343-346. PMID: 38059660, PMCID: PMC11032222, DOI: 10.1111/ajad.13504.Peer-Reviewed Original ResearchAssociations Between Childhood Trauma and Tobacco Use Outcomes in Adults after Overnight Abstinence
Palmisano A, Schwartz E, Gueorguieva R, Sofuoglu M. Associations Between Childhood Trauma and Tobacco Use Outcomes in Adults after Overnight Abstinence. Nicotine & Tobacco Research 2023, 26: 324-332. PMID: 37565294, PMCID: PMC10882440, DOI: 10.1093/ntr/ntad135.Peer-Reviewed Original ResearchSevere nicotine dependenceNicotine dependenceCotinine levelsChildhood traumaWithdrawal severityOvernight abstinenceSmoking outcomesAbuse groupHigher plasma cotinine levelsTrauma subscalesPlasma cotinine levelsNegative affectSmoking-related outcomesPublic health interventionsStudies of adultsTobacco use outcomesSevere childhood traumaChildhood trauma historyCessation interventionsMinimal groupsSmoking riskBiochemical assessmentSmoking behaviorSmoking urgesPlasma cortisolDelta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor systemDeveloping non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence
Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino J. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review Of Psychiatry 2023, 35: 377-396. PMID: 38299655, PMCID: PMC10835074, DOI: 10.1080/09540261.2023.2229430.Peer-Reviewed Original ResearchOpioid agonist therapyOpioid use disorderNon-opioid analgesicsUse disordersNon-opioid analgesic therapyAlpha-2 adrenergic agonistsMajor public health concernGlial activation inhibitorNon-opioid therapeuticsNovel analgesic strategiesPotential of cannabinoidsPrior opioid exposureOpioid-dependent individualsOpioid-dependent populationsAbuse liability assessmentPublic health concernAnalgesic strategiesAgonist therapyAnalgesic therapyOpioid exposureOUD treatmentPharmacokinetic interactionsGABAergic drugsSignificant morbidityPain typesPharmacological Interventions for Impulsivity in Addictive Disorders
Schwartz E, Palmisano A, Sofuoglu M. Pharmacological Interventions for Impulsivity in Addictive Disorders. Current Addiction Reports 2023, 10: 149-165. DOI: 10.1007/s40429-023-00486-3.Peer-Reviewed Original ResearchAddictive disordersPharmacological interventionsAddiction-related outcomesRecent FindingsSeveral studiesGlutamatergic medicationsGlutamatergic systemPatient populationPharmacological treatmentTreatment approachesMedicationsDisorder outcomesDisordersFurther studiesOutcomesInterventionImpulsivityAddictive behaviorsFacets of impulsivityMore standardizationTrait impulsivityPositive signalsDopaminergic